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Expansion of viral variants 
associated with immune escape 
and impaired virion secretion in 
patients with HBV reactivation 
after resolved infection
Tadashi Inuzuka1,2,3, Yoshihide Ueda1, Soichi Arasawa1, Haruhiko Takeda1,3, 
Tomonori Matsumoto  1,3, Yukio Osaki4, Shinji Uemoto5, Hiroshi Seno1 & 
Hiroyuki Marusawa1,4
HBV reactivation could be induced under immunosuppressive conditions in patients with resolved 
infection. This study aimed to clarify the viral factors associated with the pathogenesis of HBV 
reactivation in association with the immunosuppressive status. Whole HBV genome sequences 
were determined from the sera of 24 patients with HBV reactivation, including 8 cases under strong 
immunosuppression mediated by hematopoietic stem cell transplantation (HSCT) and 16 cases 
without HSCT. Ultra-deep sequencing revealed that the prevalence of genotype B and the ratio of non-
synonymous to synonymous evolutionary changes in the surface (S) gene were significantly higher 
in non-HSCT cases than in patients with HSCT. Those non-synonymous variants included immune 
escape (6/16 cases) and MHC class II-restricted T-cell epitope variants (6/16 cases). Furthermore, 
reactivated HBV in 11 of 16 (69%) non-HSCT cases possessed substitutions associated with impaired 
virion secretion, including E2G, L77R, L98V, T118K, and Q129H in the S region, and M1I/V in the PreS2 
region. In conclusion, virologic features of reactivated HBV clones differed depending on the intensity 
of the immunosuppressive condition. HBV reactivation triggered by immunosuppressive conditions, 
especially those without HSCT, was characterized by the expansion of variants associated with immune 
escape, MHC class II-restricted T-cell epitope alterations, and/or impaired virion secretion.
Hepatitis B virus (HBV) infection is a major global health problem, and approximately 257 million people are 
estimated to be carriers of hepatitis B surface antigen (HBsAg)-positive HBV1. HBV persists in the liver after 
the disappearance of HBsAg in individuals with previous exposure to the virus, maintaining the serologic foot-
print of the antibody to hepatitis B core antigen (anti-HBc) positivity2. An estimated 2 billion people worldwide 
with resolved HBV infection are serologically HBsAg-negative and anti-HBc–positive3. Accumulating evidence 
indicates that individuals with resolved infection carry a risk for HBV reactivation when they receive immuno-
suppressive therapy or cytotoxic chemotherapy4. Therefore, screening for not only HBsAg but also anti-HBc and/
or the antibody to HBsAg (anti-HBs) is essential before administering immunosuppressive therapy or cytotoxic 
chemotherapy, and monitoring HBV DNA and early intervention with nucleos(t)ide analogues reduces hepatitis 
caused by HBV reactivation in individuals with resolved infection5,6.
The frequencies of HBV reactivation during/after immunosuppressive therapy or cytotoxic chemotherapy 
vary according to the host immune system and HBV infection status. Previous studies reported the clinical factors 
associated with HBV reactivation in patients with resolved infection, which include male sex, disease type, and 
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those that were low anti-HBs and/or high anti-HBc before viral reactivation7–9. The intensity of immunosup-
pression is also likely to have a decisive influence on the risk of viral reactivation. Indeed, patients treated with 
hematopoietic stem cell transplantation (HSCT) carry the highest risk for HBV reactivation, with frequencies 
ranging from 14% to 41%6,10. Patients treated with HSCT have the highest risk of HBV reactivation probably due 
to strong immunosuppression, but also to the loss of their previously acquired immunity against HBV11. Little is 
known, however, about the association between the types of immunosuppressive therapy and the virologic factors 
in the pathogenesis of HBV reactivation in patients with resolved infection.
We previously demonstrated that resolved HBV carriers with the G1896A variant (guanine to adenine mutant 
at nucleotide 1896) in the precore gene of the HBV genome might have an increased risk of HBV reactivation and 
fatal acute liver failure12. Our findings suggested that not only host factors, but also viral factors, play a critical 
role in the risk of HBV reactivation from resolved infection under immunosuppressive conditions. Consistently, 
recent studies demonstrated that immune escape variants with specific amino acid substitutions in the major 
hydrophilic region in the small surface (S) protein encoded by the S gene of the HBV genome were detectable in 
the sera of patients with HBV reactivation7,13. In addition, substitutions with an additional N-linked glycosylation 
(NLG) site, which cause the addition of glycans to asparagine residues, were detectable in the small S protein in a 
subset of patients with viral reactivation13. Whether variants with altered S protein emerge after viral exacerbation 
or whether individuals with resolved HBV infection having those variants are at high risk for viral reactivation, 
however, is not clear.
In the present study, we used an ultra-deep sequencing technique to clarify the significance of viral variants in 
the pathophysiology of HBV reactivation in patients with resolved infection. To determine the virologic factors 
associated with various types of immunosuppressive therapy, we compared the viral genome in patients with 
resolved HBV infection who received immunosuppressive therapy or cytotoxic chemotherapy with and without 
HSCT. We also examined the characteristics of the viral genome in the liver of individuals with resolved HBV 
infection who did not experience viral reactivation.
Results
Reactivation of genotype B HBV was prevalent in patients under immunosuppressive condi-
tions without HSCT. This study included 24 patients with a diagnosis of HBV reactivation after resolved 
infection, including 16 patients (67%) who underwent immunosuppressive therapy or cytotoxic chemotherapy 
without HSCT (non-HSCT group) and 8 patients (33%) who underwent HSCT (HSCT group) prior to HBV 
reactivation (Table 1). In total, 17 of 24 (71%) patients were male, with a median age of 66 (range, 25–87) years. 
The median patient age was significantly younger in the HSCT group than in the non-HSCT group (59 vs 73, 
respectively; p < 0.01). Of the 24 patients, 21 (88%) had a hematologic malignancy, including 11 patients with 
malignant lymphoma, 5 with multiple myeloma, 4 with acute leukemia, and 1 with primary macroglobuline-
mia. The remaining three patients had colon cancer, lung cancer, and psoriasis, respectively. Before HBV reac-
tivation, all patients were originally HBsAg-negative, but anti-HBc-positive. Of the 24 patients, 8 (33%) were 
anti-HBs-positive, 7 (29%) were anti-HBs-negative, and in 9 (38%) patients, the anti-HBs status before viral reac-
tivation was unknown. Pre-reactivation sera from 12 patients were available for further analysis, and confirmed 
that serum HBV DNA was undetectable in the repeated PCR. Other than the median age, the clinical factors did 
not differ significantly between the non-HSCT and HSCT groups.
At the time of diagnosis with HBV reactivation, the median HBV-DNA level was 5.6 (range, 1.7–8.2) log IU/
ml in the non-HSCT group and 7.5 (range, 2.7–8.2) log IU/ml in the HSCT group. The median alanine transami-
nase (ALT) level was 68 (range, 10–2028) IU/l in the non-HSCT group and 29 (range, 15–1915) IU/l in the HSCT 
group. The median white blood cell counts, neutrophil counts and lymphocyte counts were 4140/µl (range, 1100–
22620/µl), 2540/µl (range, 240–20810/µl) and 1050/µl (range, 0–3510/µl), respectively, in the non-HSCT group 
and 5750/µl (range, 4050–7100/µl), 3440/µl (range, 2800–5400/µl) and 1260/µl (range, 320–1900/µl), respectively, 
in the HSCT group. In this study, we investigated the viral genome of 23 patients with acute hepatitis B (AHB) as 
a control. At the time of diagnosis with AHB, the median HBV-DNA level was 4.5 log IU/ml (range, 1.8–8.2 log 
IU/ml) and the median ALT level was 1992 IU/l (range, 404–4062 IU/l). The median white blood cell counts, 
neutrophil counts and lymphocyte counts were 5980/µl (range, 3790–15870/µl), 3300/µl (range, 1800–8760/µl) 
and 1930/µl (range, 1050–5520/µl), respectively, in the AHB group. The HBV-DNA level in the AHB group at the 
time of diagnosis was significantly lower than that in the non-HSCT and HSCT groups (p < 0.01). On the other 
hand, the ALT level in the AHB group was significantly higher than that in the non-HSCT and HSCT groups 
(p < 0.01). The neutrophil count was not significantly different between any two groups among the non-HSCT, 
HSCT, and AHB groups. The white blood cell count in the AHB group was significantly higher than that in the 
non-HSCT group (p < 0.05), and the lymphocyte count in the AHB group was significantly higher than that in 
the non-HSCT and HSCT groups (p < 0.05). We first determined the genotype/subgenotype of the reactivated 
viruses based on the HBV genome sequence in each case. Of note, the phylogenetic analyses revealed that 9 of 
16 (56%) cases in the non-HSCT group had reactivation of genotype B viruses, including 7 subgenotype B1/Bj 
and 2 subgenotype B2/Ba (Table 1 and Supplementary Fig. S3). In contrast, none of the cases in the HSCT group 
had genotype B, but all had genotype C (subgenotype C2/Ce). The circulating HBV in the AHB group showed 
genotype B infection in only 3 of 23 (13%; 1 was subgenotype B1/Bj and 2 were subgenotype B2/Ba), and the 
remaining 20 (87%) were genotype C HBV (2 were subgenotype C1/Cs and 18 were subgenotype C2/Ce). These 
findings indicated that reactivation of genotype B HBV was prevalent in patients with resolved infection that 
received immunosuppressive therapy and/or cytotoxic chemotherapy without HSCT.
Non-synonymous variants were accumulated in the S gene of the reactivated HBV especially 
in patients without HSCT. Ultra-deep sequencing determined viral genome sequences with a mean 
53,636-fold coverage at each nucleotide site for serum specimens from non-HSCT cases, a mean 62,132-fold 
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coverage for those from HSCT cases, and a mean 48,025-fold coverage for those from AHB cases (Supplementary 
Table S1). As we reported previously, the genetic heterogeneity of the viruses extracted from patients with HBV 
reactivation was quite low in each case12. In fact, the median number of nucleotide variants that accounted for 
more than 5% and 20% of the heterogeneity was 7.5 bases (0.2%) [range, 0–79 bases (0–2.5%)] and 2.5 bases 
(0.08%) [range, 0–44 bases (0–1.4%)], respectively, in 3215 whole bases (Supplementary Table S2). From this 
result, we selected the major strain as the representative sequence in each case by ultra-deep sequencing and used 
it for the following analyses.
First, we confirmed that there was no significant difference in the total number of nucleotide variants of the 
HBV genome among the non-HSCT, HSCT, and AHB groups (Fig. 1A). We then examined the proportion of 
non-synonymous variants among the total nucleotide variants in the reactivated viruses of each group. Because 
HBV partially overlaps four open reading frames encoding the surface antigen, nucleocapsid, X protein (X), 
and polymerase (Pol), we separately estimated the total number of amino acid variants in the presurface (PreS) 
domain, S protein, X, precore/core (PreC/C), and Pol coding regions of the HBV genome. As shown in Fig. 1B, 
the total number of amino acid variants was significantly greater in the reactivated viruses of the non-HSCT 
group than in those of the AHB group (p < 0.05). In addition, amino acid variants tended to be more abundant in 
the non-HSCT group than in the HSCT group, although the difference was not statistically significant (p = 0.25).
To clarify the viral proteins that contained amino acid variants in the reactivated viruses, we determined 
the distribution of non-synonymous and synonymous variants in each HBV protein coding sequence in the 
non-HSCT cases. Synonymous variants were predominant in the Pol regions (p < 0.01), and there was no signif-
icant difference between the non-synonymous and synonymous variants in the PreS, X, and PreC/C regions. In 
contrast, non-synonymous variants were prevalent in the S region of the reactivated viruses (p < 0.01; Fig. 1C). 
To compare the frequencies of amino acid variants in the small S protein among the non-HSCT, HSCT, and AHB 
groups, we examined the number of non-synonymous and synonymous variants in the S region of the viruses in 
each group. Non-synonymous variants in the S region were prevalent in the viruses from the non-HSCT group 
compared with the HSCT and AHB groups (Fig. 1D). To estimate the putative selective pressure in the reacti-
vated HBV of non-HSCT cases, we determined the non-synonymous (dN) and synonymous (dS) substitution 
rates (dN/dS ratios) in each HBV protein-coding region. The dN/dS values of viruses can be greater than one 
when they are subject to positive selection (adaptive evolution)14. Of note, viruses with a dN/dS ratio greater than 
one were prevalent in the S region among all HBV proteins, especially in non-HSCT cases (Fig. 1E). Namely, 
Patients’ Characteristics
non-HSCT group HSCT group AHB group
(n = 16) (n = 8) (n = 23)
Gender (M/F) 11/5 6/2 15/8
Median age (years) 73 (52–87) 59 (25–66) 41 (21–76)
Primary disease
  Malignant lymphoma 9 (56%) 2 (25%) —
  Multiple myeloma 2 (13%) 3 (38%) —
  Leukemia 1 (6%) 3 (38%) —
  Chronic inflammatory diseases 1 (6%) 0 (0%) —
  Other diseases 3 (19%) 0 (0%) —
Immunosuppressive therapy, N (%)
  Hematopoietic Stem Cell Transplantation 0 (0%) 8 (100%) —
  Rituximab-containing chemotherapy 10 (63%) 1 (13%) —
  Other cytotoxic chemotherapy 5 (31%) 0 (0%) —
  Other immunosuppressive therapy 1 (6%) 0 (0%) —
Prereactivation HBV status, N (%)
  Isolated anti-HBc positive 5 (31%) 2 (25%) —
  Anti-HBc positive/anti-HBs positive 3 (19%) 5 (63%) —
  Anti-HBc positive/unknown anti-HBs status 8 (50%) 1 (13%) —
  Median HBV DNA, log IU/ml 5.6 (1.7–8.2) 7.5 (2.7–8.2) 4.5 (1.8–8.2)
  Median ALT, IU/l 68 (10–2028) 29 (15–1915) 1992 (404–4062)
Median white blood cell counts
  White blood cell counts, /µl 4140 (1100–22620) 5750 (4050–7100) 5980 (3790–15870)
  Neutrophil counts, /µl 2540 (240–20810) 3440 (2800–5400) 3300 (1800–8760)
  Lymphocyte counts, /µl 1050 (0–3510) 1260 (320–1900) 1930 (1050–5520)
HBV subgenotype
  B1/Bj 7 (44%) 0 (0%) 1 (4%)
  B2/Ba 2 (13%) 0 (0%) 2 (9%)
  C1/Cs 0 (0%) 0 (0%) 2 (9%)
  C2/Ce 7 (44%) 8 (100%) 18 (78%)
Table 1. Clinical characteristics of the patients with HBV reactivation and acute hepatitis B.
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in the non-HSCT group, 11 of 14 (79%) cases had HBV S regions with a dN/dS ratio greater than one (Fig. 1F). 
In contrast, in the HSCT and AHB groups, three of seven (43%) and one of nine (11%) cases, respectively, had 
circulating viruses with a dN/dS ratio greater than one in the S region. These findings suggest that viruses with 
non-synonymous variants in the S region were positively selected, especially in patients with HBV reactivation 
in the non-HSCT group.
Figure 1. Comparison of nucleotide and amino acid variants among patients with HBV exacerbation in the 
non-HSCT, HSCT, and AHB groups. Difference in the number of nucleotide variants in the full HBV genome (A) 
and amino acid variants (B) among the non-HSCT, HSCT, and AHB groups (Kruskal-Wallis test and following 
Steel-Dwass test for post hoc analysis). The PreS represents the domain that is coded by the PreS1 and PreS2 
genes. (C) The mean number of nucleotide variants per nucleotide in each HBV protein coding region of viral 
genome in the non-HSCT group and (D) the total number of nucleotide variants in the S gene among the three 
groups. The bar represents the median value. The asterisk indicates a statistically significant difference between 
the synonymous and non-synonymous variants (p < 0.01, Mann–Whitney U test). (E) The dN/dS values of each 
viral protein among the three groups. (F) The frequencies of cases whose dN/dS ratio was greater than one in 
each viral protein among the three groups. The asterisk indicates a statistically significant difference among the 
three groups (p < 0.05, chi-square test). Abbreviations: AHB, acute hepatitis B, HSCT, hematopoietic stem cell 
transplantation, Pol, polymerase, PreC/C, precore/core protein, PreS, presurface, S, surface, X, X protein.
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High prevalence of HBV with immune escape and/or MHC class II-restricted T-cell epitope variants 
in the reactivated viruses. All amino acid variants detected in the small S protein of 24 patients at HBV 
reactivation are shown in Fig. 2. First, we detected a number of amino acid substitutions in the major hydrophilic 
region, including the amino acid 124–147 region encoding the dominant neutralizing B-cell epitope defined as 
the ‘a’ determinant region in non-HSCT cases15. Amino acid substitutions associated with immune escape, such 
as sT118K (n = 3), sG145A (n = 3), and sG145R (n = 1) variants13,15–20, were abundant, especially in non-HSCT 
patients at HBV reactivation. Moreover, three patients in the non-HSCT group had predominant variants with 
sT116N, sT123N, and sG130N changes, which resulted in the addition of NLG sites by substitutions of threonine 
or glycine with asparagine. These additional NLG sites in the small S protein associate with impaired HBsAg 
recognition of anti-HBs antibodies caused by the masking B-cell epitope13,19,21.
Next, we also identified amino acid substitutions sL21S (n = 3) and sF220C (n = 4) in the MHC class 
II-restricted T-cell epitope region, which are reported to cause a complete loss of T-cell reactivity and anti-HBs 
production among individuals vaccinated against HBV in an ex vivo study22. All six patients with MHC class 
Figure 2. Prevalence of HBV variants in the small S protein in patients with HBV reactivation under 
immunosuppressive therapies and/or cytotoxic chemotherapies. Amino acids harbored by each reference 
sequence are shown on the left side. Only positions with amino acid substitutions as compared to HBV 
reference sequences are shown, and the dash indicates the absence of an amino acid substitution. R1-24 are the 
cases with HBV reactivation. MHC class II on the left side means the MHC class II-restricted T-cell epitope 
region. (A) Patients with genotype B HBV in the non-HSCT group. (B) Patients with genotype C HBV in the 
non-HSCT group. (C) Patients with genotype C HBV in the HSCT group. Abbreviation: HSCT, hematopoietic 
stem cell transplantation.
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II-restricted T-cell epitope substitutions were in the non-HSCT group, while none of the patients in the HSCT 
and AHB groups had MHC class II-restricted T-cell epitope substitutions (Figs 2 and S1).
In total, 10 of 16 (63%) cases in the non-HSCT group had a dominant population of variants associated with 
immune escape and/or MHC class II-restricted T-cell epitope alterations, which could affect the adaptive immune 
system (Fig. 3A). In contrast, in the HSCT group, only two of eight (25%) cases had immune escape variants and 
none of those cases possessed MHC class II-restricted T-cell epitope variants (Fig. 3B). No patients in the AHB 
group had any variants in those regions (Supplementary Fig. S1). These findings suggest that variants with puta-
tive escape from the immune response against HBV play a critical role in viral reactivation, especially in patients 
that receive immunosuppressive therapy or cytotoxic chemotherapy without HSCT.
Variants with a phenotype of impaired virion secretion were prevalent in patients with HBV 
reactivation. Previous studies demonstrated that several variants in the S region of the HBV genome could 
lead to reduced secretion of virions from the infected hepatocytes17,23. In addition, several variants in the immu-
nodominant loop of surface protein, including sT118K, sQ129H, and sG145R substitutions in the small S protein 
are reported to induce impaired virion secretion from infected liver cells17,20. Interestingly, sT118K (n = 3) and 
sQ129H (n = 2) variants were predominant in patients in the non-HSCT group, and sG145R was detected in one 
Figure 3. HBV variants with immune escape, MHC class II-restricted T-cell epitope alterations and/or 
impaired virion secretion in patients with HBV reactivation. The prevalence of characteristic amino acid 
substitutions in the small S protein (A) in the non-HSCT and (B) HSCT groups. R1-24 are the cases with HBV 
reactivation. (C) The reactivated viral clones in four cases (R4, R6, R7, and R12) of the non-HSCT group were 
variants with the M1I/V substitution at the PreS2 start codon, which resulted in the ablation of the middle S 
protein. Abbreviation: HSCT, hematopoietic stem cell transplantation.
www.nature.com/scientificreports/
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patient in the HSCT group (Fig. 2). Amino acid substitutions of sE2G (n = 3), sL77R (n = 1), and sL98V (n = 1) 
in the small S protein that were associated with impaired virion secretion were also the predominant clone in 
patients in the non-HSCT group24,25. In total, the small S protein variants associated with impaired virion secre-
tion were detected as the predominant clones in 8 of 16 (50%) patients with HBV reactivation under immunosup-
pression without HSCT, but in only 1 of 8 (13%) patients with HSCT (Fig. 3A,B).
The middle S protein of HBV is reported to be dispensable for virion formation and secretion26, and deficiency 
of middle S protein production could result in impaired virion secretion27. Interestingly, M1I/V variants at the 
start codon of the PreS2 gene, resulting in defective expression of the middle S protein, were also detected in 
the reactivated viruses of patients in the non-HSCT group. Indeed, ultra-deep sequencing analysis showed that 
almost all the reactivated viral clones in four cases in the non-HSCT group were variants with the M1I/V substi-
tution at the PreS2 start codon (frequency of 99.7% to 99.9% for total viral population), suggesting that these viral 
clones also impaired virion secretion caused by a deficiency of middle S protein production (Figs 3C and 4). In 
contrast, none of the patients in the HSCT and AHB groups had those PreS2 variants in their serum at the time 
of HBV exacerbation (Figs 4 and S2).
Taken together, 11 of 16 (69%) patients in the non-HSCT group had a dominant population of the HBV S or 
PreS2 variants associated with a putative phenotype of impaired virion secretion, while only 1 of 8 (13%) patients 
in the HSCT group and none in the AHB group possessed the variants associated with impaired virion secretion.
Low prevalence of viral clones with altered S protein in the liver of individuals with resolved 
HBV infection. To clarify whether viral clones with various variants in the S region pre-existed in the liver 
before reactivation or were selected for and became dominant with the acquisition of those variants after reac-
tivation, we determined the prevalence of HBV variants in the S gene in the liver of individuals with resolved 
infection without viral reactivation. For this purpose, we determined the sequences of the S region of the HBV 
genome in the liver tissues of HBsAg-negative, but anti-HBc-positive, healthy donors for living-donor liver trans-
plantation (LDLT). Whole S gene sequences of HBV were successfully amplified from the liver from 62 of 90 
(69%) individuals with resolved infection. Ultra-deep sequencing achieved a mean coverage depth of 36,047 bp 
for each nucleotide site of the HBV sequences (Supplementary Table S3). The phylogenetic analyses of the HBV 
Figure 4. Amino acid variants of the PreS1/PreS2 coding domain in patients with HBV reactivation under 
immunosuppressive therapies and/or cytotoxic chemotherapies. Amino acids harbored by each reference 
sequence are shown on the left side. Only positions with amino acid substitutions as compared with HBV 
reference sequences are shown, and the dash indicates the absence of an amino acid substitution. R1-24 are 
the cases with HBV reactivation. (A) Patients with genotype B HBV in the non-HSCT group. (B) Patients with 
genotype C HBV in the non-HSCT group. (C) Patients with genotype C HBV in the HSCT group. Abbreviation: 
HSCT, hematopoietic stem cell transplantation, PreS, presurface.
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genome sequences revealed that 2 (3%) patients had genotype A, 3 (5%) had subgenotype B1/Bj, 5 (8%) had 
subgenotype B2/Ba, and the remaining 52 (84%) had subgenotype C2/Ce, indicating that the prevalence of geno-
type B was relatively lower than the prevalence of reactivated viral isolates in patients under immunosuppressive 
conditions without HSCT. To compare the prevalence of amino acid substitutions with that of the reactivated 
viral clones, we focused on 60 samples infected with genotype B or C HBV from the liver of individuals with 
resolved infection. Baseline clinical characteristics of 60 individuals with resolved infection are summarized in 
Supplementary Table S4. We found very few amino acid variants (median 1, range 0–8 per 226 amino acids) of 
the small S protein in the liver of individuals with resolved HBV infection, compared with those of the reactivated 
viruses in the sera of patients in the non-HSCT group (median 5, range 0–25 per 226 amino acids; Figs 2 and 
5A). Further, 5 of 60 (8%) individuals had intrahepatic infection by HBV with variants potentially associated with 
either immune escape (n = 1), MHC class II-restricted T-cell epitope changes (n = 2), or reduced secretion of 
virions (n = 3) in their liver tissues with a variety of frequencies for total viral clones (median 67.3%, range, 1.9% 
to 99.9%; Fig. 5B and Supplementary Table S5). These findings indicate that the prevalence of HBV variants with 
altered small S protein in the latently infected liver was much lower than that of the reactivated viral clones under 
immunosuppression.
Expansion of viral clones with mutations in the S region in an individual with resolved HBV 
infection. We evaluated the viral dynamics of variants with altered S protein in detail in one patient whose 
serum samples during the time-course of HBV reactivation was available for sequencing analyses. The clinical 
course of this patient is shown in Fig. 6. Case R22 was originally HBsAg-negative, but anti-HBc positive, and 
received HSCT for a diagnosis of myelodysplastic syndrome-overt leukemia. HBV DNA in the serum became 
positive over 6 years after HSCT, followed by positivity for HBsAg. Among the whole HBV genome, only 3 (0.1%) 
of 3215 nucleotides substantially changed in the predominant viral clones during viral reactivation. These three 
altered nucleotides included non-synonymous mutations in the S gene coding region; sG145A, sE164D, and 
s*223 W (conversion of a stop codon into a tryptophan codon) alterations. Of note, the frequency of sG145A 
Figure 5. Prevalence of viral variants with altered S protein in the liver of individuals with resolved HBV 
infection. (A) The prevalence of amino acid variants in the small S protein (226 amino acids) of genotype 
B/C HBV infected liver in individuals with resolved infection (n = 60). (B) Of 60 individuals, 5 (8%) showed 
intrahepatic infection by variants potentially associated with either immune escape (n = 1), MHC class II-
restricted T-cell epitope changes (n = 2), or reduced secretion of virions (n = 3) in their liver tissues.
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variants, representing immune escape variants, increased from 0% to 86.1% for the total viral population in 
accordance with an increase in HBV DNA levels from 2.4 log IU/ml to 8.2 log IU/ml. Finally, more than 99% 
of all the circulating HBV isolates became sG145A variants, followed by a subsequent decrease in the viral load 
mediated by administration of the nucleoside analogue entecavir. Variants with the sE164D substitution also 
increased from 0% to 99.5% for the total population, and variants with the s*223 W substitution expanded 
from 8.3% to 99.4% of the circulating viral isolates, while the virologic significance of these two substitutions 
remained unknown. Together with the low prevalence of HBV variants with altered S protein in the liver of indi-
viduals without immunosuppressive conditions, these findings suggest that several mutations associated with the 
anti-viral immune response might newly emerge on infected viral clones after viral reactivation under immuno-
suppressive conditions.
Discussion
It is well recognized that individuals with resolved HBV infection can develop viral reactivation, so-called de novo 
HBV reactivation, in response to immunosuppressive therapy and/or cytotoxic chemotherapy. The viral factors 
attributed to HBV reactivation after the resolved infection are not fully understood because of the low incidence 
of HBV reactivation among HBsAg-negative, but anti-HBc-positive, individuals under immunosuppressive con-
ditions. In the present study, we investigated the virologic features of reactivated HBV in patients with resolved 
infection in association with the type of the immunosuppressive condition.
Increasing evidence suggests that the incidence of viral reactivation differs depending on the type of the 
immunosuppressive condition. Immunosuppression in patients receiving HSCT is associated with an especially 
high risk of HBV reactivation, ranging from 14% to 41%6,10. In contrast, the incidence of viral reactivation in 
patients receiving immunosuppressive therapy and/or cytotoxic chemotherapy without HSCT was relatively low 
compared to that in patients with HSCT3. In this study, we revealed that the genotype of the reactivated HBV 
clearly differed between immunosuppressed patients with and without HSCT. In the non-HSCT group, 9 of 16 
(56%) patients had genotype B HBV, including 7 cases with subgenotype B1/Bj viral clones. In sharp contrast to 
those without HSCT, no patients who received HSCT developed HBV reactivation with genotype B, but all cases 
had genotype C viral reactivation. A large Japanese cohort study reported that 12.2% and 84.7% of patients with 
chronic HBV infection had genotype B and genotype C, respectively28, indicating that genotype B is a minor gen-
otype in Japan. Interestingly, genotype B constructs with a wild-type core promoter sequence mostly displayed 
higher replication capacities than the corresponding genotype C constructs due to more efficient transcription of 
the 3.5-kb RNA29,30. Thus, it may be that strong immunosuppressive conditions mediated by HSCT could provide 
the opportunity for reactivation for genotype C viruses, while genotype B reactivation was achieved in patients in 
the non-HSCT group due to their ability to replicate at high levels compared with genotype C isolates.
Ultra-deep sequencing revealed that non-synonymous variants were abundant in the reactivated HBV of 
non-HSCT patients compared to cases with HSCT. Of note, the dN/dS ratios in the S region of the reactivated 
Figure 6. Viral dynamics of variants with altered S protein in the representative case with HBV reactivation. 
A case (R22) that acquired an immune escape mutation, sG145A, in the small S protein during the process of 
HBV reactivation. The frequency of sG145A variants in four serum samples at different time-points, analyzed 
by ultra-deep sequencing, is shown in the lower panel. Abbreviation: ALT, alanine transaminase, anti-HBs, 
antibody to HBsAg, GVHD, graft versus host disease, HSCT, hematopoietic stem cell transplantation.
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viruses were significantly higher in the non-HSCT cases than in HSCT or AHB patients. Indeed, HBV S regions 
with dN/dS ratios greater than one were frequently observed in 11 of 14 (79%) cases in the non-HSCT group, 
while they were observed in only 3 of 7 (43%) and 1 of 9 (11%) of cases in the HSCT and AHB groups, respec-
tively. These findings suggest that variants with amino acid changes of the S protein were positively selected, 
especially in patients under immunosuppression without HSCT. Interestingly, amino acid substitutions observed 
in the reactivated HBV frequently included those putatively associated with impairment of the anti-HBs immune 
response. For example, 8 of 24 (33%) patients with HBV reactivation after resolved infection had viral isolates 
with immune escape variants in the S gene. Moreover, 6 of 24 (25%) patients had sL21S and/or sF220C amino 
acid variants in the MHC class II-restricted T-cell epitope of the small S protein, potentially leading to a complete 
loss of T-cell reactivity and anti-HBs production22. Of note, 10 of 16 (63%) patients in the non-HSCT group had 
those variants with the small S protein substitutions, including six cases (38%) with immune escape variants, and 
six (38%) with MHC class II-restricted T-cell epitope variants. These findings suggest that viral isolates that could 
escape the host’s acquired immunity to impaired reactivity with B cells and/or MHC class II-restricted T cells are 
frequently involved in the pathogenesis of HBV reactivation after resolved infection, especially in patients receiv-
ing immunosuppressive therapies and/or cytotoxic chemotherapies without HSCT. In comparison with reacti-
vated viruses in patients without HSCT, those in patients with HSCT had few amino acid variants and only two 
of eight (25%) patients had amino acid substitutions associated with impairment of anti-HBV immune responses 
in the S region. As the previous study revealed that HSCT recipients who originally had latent HBV infection in 
their livers gradually lost their acquired HBV immunity (reaching 90% loss at 5 years) after HSCT11, we suppose 
that the anti-HBV immune response would differ between patients with HSCT and those without HSCT, leading 
to the different genetic features of the reactivated HBV.
Several studies demonstrated that specific amino acid substitutions in the S gene of HBV impair virion 
secretion from cells to the culture supernatant in vitro17,23,27. In the clinical setting, variants with a phenotype of 
impaired virion secretion are found in patients chronically infected with HBV. Xiang et al. demonstrated that 3 
of 230 (1.3%) hepatitis B e antigen-positive chronic hepatitis B patients were infected with sE2G variants, 9 of 
230 (3.9%) were infected with sL98V variants, and 3 of 230 (1.3%) were infected with sG145R variants in the 
small S protein24. The virologic and/or pathologic significance of the reduced virion secretion for HBV infection, 
however, remains unsolved. In the present study, we demonstrated that reactivated HBV frequently contained 
amino acid substitutions related to impaired virion secretion. Indeed, sE2G, sL77R, sL98V, sT118K, sQ129H, and 
sG145R, all of which cause reduced virion secretion17,20,24,25, were found in the sera from 9 of 24 (38%) patients 
with HBV reactivation. It is well established that viruses lacking middle S protein production can form a viral 
structure, but reduce virion secretion26,27. In addition, Pollicino et al. demonstrated that PreS/S variants caused 
an imbalance in the synthesis of the S proteins31. Interestingly, 4 of 16 (25%) patients in the non-HSCT group 
developed HBV reactivation by variants with the M1V/I substitution at the PreS2 start codon, leading to ablation 
of the middle S protein. In contrast, variants in the S and/or PreS2 coding domain associated with reduced virion 
secretion were detected in only one case in the HSCT group and none in the acute hepatitis patients. Why viral 
clones with impaired virion secretion were predominantly detected in patients with HBV reactivation, however, 
remains unknown. One possibility is that the impaired virion secretion from the infected cells reduces the oppor-
tunities for circulating viruses to encounter the immune cells in the early phase of HBV reactivation, and thus 
may afford viruses the chance to acquire additional variants to escape from immune response and/or to replicate 
more efficiently for viral exacerbation.
An unanswered question is whether all these specific variants in the S gene are acquired after viral reactiva-
tion, or whether the latently infected HBV in the liver originally contained these S gene variants. To gain insight 
into the dynamics of variants during HBV reactivation, we examined the viral genome sequences of S region 
in the liver of 62 individuals with resolved HBV infection. We found that the prevalence of HBV variants with 
altered small S protein was significantly lower in the liver of individuals with resolved infection than in the sera of 
patients with HBV reactivation. These findings suggest that HBV variants with altered small S protein associated 
with immune escape and/or impaired virion secretion emerged and expanded after viral reactivation. Consistent 
with this hypothesis, the appearance of HBV variants with S protein substitution was observed in the sera of 
one representative case with viral reactivation. Taken together, these findings suggest that latently infected HBV 
clones could acquire several variants in the S region and the viral isolates that acquired the altered small S protein 
associated with immune escape are selected for and become dominant in the process of HBV reactivation.
In conclusion, ultra-deep sequencing analyses demonstrated differences in the virologic features of the reacti-
vated HBV clones between immunosuppressed patients with and without HSCT. Expansion of viral variants with 
an accumulation of amino acid substitutions in the S and PreS2 region was frequently observed in cases with-
out HSCT compared to those with strong HSCT-mediated immunosuppression and loss of acquired anti-HBV 
immunity. These amino acid substitutions in the S and PreS2 region frequently included those associated with 
immune escape, MHC class II-restricted T-cell epitope alterations, and/or impaired virion secretion. Those vari-
ants in the S gene might newly emerge after reactivation and selectively expand under anti-HBs immune pressure 
in patients with originally resolved HBV infection. From these findings, we supposed that a subset of anti-HBV 
immune response-related variants could newly emerge during viral exacerbation and play a role in the pathogen-
esis of HBV reactivation under immunosuppressive conditions, especially in cases receiving immunosuppressive 
therapy and/or cytotoxic chemotherapy without HSCT.
Methods
Patients and Samples. Between April 2007 and December 2016, 24 patients who were HBsAg-negative 
and anti-HBc-positive prior to the initiation of immunosuppressive therapy or cytotoxic chemotherapy were 
diagnosed with HBV reactivation at Kyoto University Hospital and affiliated hospitals. All patients were originally 
HBsAg-negative, but anti-HBc-positive, before HBV reactivation, and lacked any risk factors for external viral 
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transmission. All patients were longitudinally followed up at 0.5–3 month intervals until analysis (November 
2017) or death. Twenty-three patients with AHB were randomly selected as controls.
Serum samples were obtained at diagnosis of HBV reactivation based on the appearance of circulating HBV 
DNA under immunosuppressive conditions. All serum samples were frozen and stored at −80 °C until used in this 
study. Serologic HBV markers, including HBsAg, anti-HBs, and anti-HBc were measured by chemiluminescent 
enzyme immunoassay (CLEIA; Fuji Rebio, Tokyo, Japan). The serum HBV DNA titer was analyzed by commercial 
PCR (COBAS Taqman HBV test; Roche, Branchburg, NJ, USA) with a lower detection limit of 1.3 log IU/ml.
To investigate the viral sequences of the S gene in the liver of individuals with resolved infection, liver tissues 
were obtained from 90 healthy donors negative for HBsAg and positive for anti-HBc who underwent hepatec-
tomy for LDLT at Kyoto University Hospital. All liver tissues were frozen and stored at −80 °C until used in this 
study.
The Kyoto University Ethics Committee approved this study, and written informed consent was obtained from 
all patients. The study was conducted in accordance with the principles of the Declaration of Helsinki.
Sequencing method. PCR and Sanger sequencing protocols for the viruses from the sera of patients with 
HBV reactivation and AHB were described previously12. Because of the low viral load in the liver of the LDLT 
donors, nested PCR was performed. To obtain whole S gene sequences, four amplicons were constructed using 
eight paired primers (Supplementary Table S6).
Ultra-deep sequencing of the HBV genome was conducted using the Ion ProtonTM Sequencer (Thermo 
Fisher Scientific, Waltham, MA, USA). HBV DNA amplicons were quantified using the Invitrogen Qubit® 2.0 
Fluorometer (Thermo Fisher Scientific). Libraries were generated using 100 ng of genomic DNA and an Ion 
Xpress Plus Fragment Library Kit with the Ion Shear Plus Reagents Kit. Amplicons were ligated to adapters 
from the Ion XpressTM Barcode Adapters. An Agilent 2200 TapeStation (Agilent Technologies, Santa Clara, CA, 
USA) was used to visualize the size range, and an Ion Library TaqMan® Quantitation Kit was used to deter-
mine the library concentration for preparation of the emulsion PCR. After dilution of each library to 100 pmol/l, 
6 µl of the library was used as a template for clonal amplification on Ion Sphere particles during emulsion PCR 
according to the Ion PITM Template OT2 200 Kit v3 User Guide. Sequencing was conducted over 520 sequencing 
cycles with the Ion PITM Hi-QTM Sequencing 200 Kit on an Ion PITM Chip v3 (Thermo Fisher Scientific). The 
above-mentioned protocol resulted in an average read length of 200–300 nucleotides.
Sequencing Data Analysis. Using high-performance alignment software, NextGENe® (ver. 2.4.2; 
SoftGenetics, State College, PA, USA), the sequence reads obtained from the Ion ProtonTM Sequencer were 
aligned with reference sequences for the entire HBV genome (3215 bp) that were determined from direct popu-
lation Sanger sequencing of each clinical specimen. Reads with ≥90% of bases matching a particular position in 
the reference sequences were aligned. Two quality filters were used for sequencing reads to remove sequencing or 
alignment errors. Variations that occurred at largely different frequencies in the forward and reverse directions, 
and ≥3 times in the 10-bp region on either side were removed. Only sequences that passed the quality filters were 
analyzed, and each position of the viral genome was assigned a coverage depth, representing the number of times 
the nucleotide position was sequenced. We defined the cut-off value in the current platform as 1% to exclude 
mismatch errors and to detect low-abundance mutations according to our previous report12.
The subgenotypes of HBV were determined by phylogenetic analysis of the full HBV genome sequences with 
the software MEGA 7.0 using control strains from the NCBI site (Supplementary Fig. S3).
To determine the nucleotide and amino acid variants, two reference genomes and amino acid sequences of 
each subgenotype from the NCBI database were used as follows: accession numbers AB246342 and AB900105 for 
subgenotype B1/Bj, AB246339 and JQ801516 for subgenotype B2/Ba, AB246346 and JQ801515 for subgenotype 
C1/Cs, and AB246345 and AB697502 for subgenotype C2/Ce. The reference sequences of each subgenotype in 
our study were mainly selected from a previous study30, which clarified the functional differences of each HBV 
subgenotype by using plasmids carrying HBV genomes extracted from cases with representative sequences from 
each subgenotype. Nucleotide/amino acid variants were defined when each nucleotide or amino acid of HBV 
sequences we determined did not exactly coincide with the respective reference alignment of each subgenotype.
The ratios of non-synonymous to synonymous evolutionary changes (dN/dS ratios) were calculated using 
PAL2NAL (http://www.bork.embl.de/pal2nal/) in each protein32. The reference sequences for dN/dS analysis were 
as follows: accession numbers AB246342 for subgenotype B1/Bj, AB246339 for subgenotype B2/Ba, AB246346 for 
subgenotype C1/Cs, and AB246345 for subgenotype C2/Ce30. To calculate the dN/dS ratios for each protein, cases 
with fewer than three nucleotide variants were excluded.
Analysis of NLG sites was performed on the S gene sequences of each HBV isolate using the program 
N-GlycoSite (https://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html). NLG targets an amino 
acid sequence motif that is defined by NXS/T, where X represents any amino acid other than proline33.
Statistical Analysis. All analyses were carried out using IBM SPSS Statistics ver. 24.0 (SPSS Inc., Chicago, 
IL, USA). The non-parametric Mann–Whitney U test was used to compare two continuous variables, and the 
Kruskal-Wallis test, followed by the Steel-Dwass test for post hoc analysis, was used to compare the three groups. 
The Fisher exact test was used to compare two categorical variables, and the chi-square test was used to compare 
three categorical variables. A P-value less than 0.05 was considered statistically significant.
Data Profiling
Sequence reads with Genome Analyzer were deposited in the DNA Data Bank of Japan Sequence Read Archive 
(http://trace.ddbj.nig.ac.jp/dra/index_e.shtml) under accession number DRA006491.
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